Albuterol has been approved in the United States and in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


albuterol studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
SBM40003 IV A single-centre, randomised, double blind, double-dummy, crossover study to measure the topical and systemic effects of salbutamol delivered by the Turbuhaler inhaler compared with the DISKUS™ dry powder inhaler at high and low inspiratory effort in adult patients with reversible obstructive airways disease.
SB030001 III A Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-Center Study of VENTOLIN™ (albuterol) HFA MDI delivered TID with facemask and valved holding chamber AEROCHAMBER™ in subjects birth to <24 months in age with symptoms of bronchospasm (i.e. wheeze, cough, dyspnea or chest tightness) consistent with obstructive airways disease. AEROCHAMBER is a trade mark of Trudell Medical VENTOLIN is a trade mark of the Glaxo SmithKline group of companies.
SB030002 III A Randomized, Double-Blind, Parallel-group, Multi-Center Study of Albuterol Sulfate HFA Inhalation Aerosol Delivered Cumulatively with a Valved Holding Chamber and an Attached Facemask in Subjects Between Birth to 23 Months of Age with Acute Wheezing Due to Obstructive Airways Disease
SB030003 III An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of Albuterol HFA with Counter in Asthma or COPD Subjects at Least 4 Years of Age.
EL110025 II A single-centre, randomised, double-blind, double-dummy, 3-period cross-over study to evaluate the effect of two single doses of inhaled NCE on the subsequent bronchodilator effect of a sub-therapeutic dose of salbutamol (10 mg administered by dosimeter) in patients with moderate asthma.
SB020001 II A Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-Center Study of VENTOLIN™ (albuterol) HFA MDI delivered with facemask and two different holding chambers in Subjects aged 24 to <48 months with asthma symptoms (i.e. wheeze, cough, dyspnea or chest tightness) or consistent with asthma or obstructive airway disease or bronchospasm.
SBM20001 II A single centre, randomised, double-blind, double-dummy, placebo-controlled, parallel group, pilot study to determine the efficacy and safety of 2mg and 4mg doses of Ventolin ™ (salbutamol) syrup for the treatment of cough associated with acute viral upper respiratory tract infection, during a 3.5 hour laboratory phase followed by an up to six days treatment home phase.
SBM20002 II A single centre, randomised, double-blind, placebo-controlled, crossover, pilot study to determine the efficacy and safety of 400 µg and 200 µg doses of Ventolin ™ salbutamol inhaler versus placebo for the treatment of smoking related cough.
AA210010 I A randomised, double-blind, placebo-controlled, rising dose, 6-way crossover study to investigate the effect on heart rate of single doses of NCE (25 mg and 50 mg) and escalating cumulative doses of salbutamol (up to 1200 mg) administered alone and in combination to healthy male smokers.
EL110003 I A single centre, randomised, double-blind, placebo-controlled, repeat dose, 4-period cross-over study to evaluate the safety, pharmacokinetics and pharmacodynamics (including the effect on QTc) of a single dose of nebulised salbutamol (5 mg), following repeat-dose administration of a new chemical entity (NCE) for 5 days in healthy male subjects.